STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
· statnews.com · popularity 32/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at statnews.com →
Summary
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 6.